On CBSNews.com: Test Your BATMAN IQ Now
Find Articles in:
all
Business
Reference
Technology
News
Sports
Health
Autos
Arts
Home & Garden
advertisement
advertisement

Content provided in partnership with
Market Wire

Protherics announces Director/PDMR Shareholding

Market Wire,  July, 2008  


Protherics PLC


Notification of Director's Interests


London, UK; Brentwood, TN, US: 10 July 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, in accordance with
Sections 3.1.4R of the FSA Disclosure and Transparency
Rules, announces that 916,202 ordinary shares (the "Shares")
 were issued to Jacques Gonella, Non-executive Director of Protherics,
on 9 July 2008 following their admission to the Official List of the
Financial Services Authority.


The Shares form part of the allotment of 1,741,911 ordinary shares
(details of which are contained in the Company's announcement dated 4
July 2008) made pursuant to the MacroMed Acquisition Agreement
(the "Agreement") approved by shareholders at the Company's
Extraordinary General Meeting held on 3 January 2007. Details of the
Agreement are contained in the Company's announcement dated 7 December
2006. In accordance with the Agreement the issue price of the
shares is 69.69 pence per share.


Following the issuance of the Shares, Dr Gonella holds a beneficial
interest in 9,162,017 ordinary shares in the
Company representing 2.677% of the issued share
capital of 342,159,034 ordinary shares.


                            / Ends /



For further information please contact:


Protherics

Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510

Julie Vickers, Company Secretary            +44 (0)1928 518010


Financial Dynamics - press enquiries

London: Ben Atwell, Lara Mott               +44 (0) 20 7831 3113

New York: John Capodanno                    +1 212 850 5600



Or visit   www.protherics.com 

                    This information is provided by RNS
          The company news service from the London Stock Exchange

END

Contacts: RNS Customer Services 0044-207797-4400 Email Contact http://www.rns.com